Substance addiction is a maladaptive behavior characterized by compulsive and uncontrolled self-administration of a substance (drug). Years of research indicate that addictive behavior is the result of complex interactions between the drug, the user, and the environment in which the drug is used; therefore, addiction cannot simply be attributed to the neurobiological actions of a drug. However, despite the obvious complexity of addictive behavior, animal models have both advanced understanding of addiction and contributed importantly to the development of medications to treat this disease. We briefl y review recent animal models used to study drug addiction and the contribution of data generated by these animal models for the clinical treatment of addictive disorders.
Introduction

I
s drug addiction a single disease or a collection of different diseases that share common features of compulsive drug use behavior? The current state of addiction research gives the impression that addiction is a collection of diseases (e.g., cocaine addiction, heroin addiction, and so forth) that share common behavioral features, although most researchers do not hold this view. The downside of this multidisease concept is that it creates challenges for the development of effective treatment strategies. For example, both cocaine and amphetamine are central nervous system stimulants, but they have completely different treatment strategies. Although it is true that these drugs exert their action through different receptors and modulate different neurotransmitter systems, the addictive nature of the drugs converges on the neurocircuitry that underlies their rewarding properties. The convergence argues for the idea that drug addiction is a single disease-a disease of the reward circuit that drives maladaptive behavioral responses to positive and/or negative reinforcement. Thus, conceptual models of drug addiction that incorporate all drug classes could signifi cantly advance understanding of the addicted brain.
This review is organized according to addiction to specifi c classes of drugs because research programs tend to focus on specifi c drugs (e.g., cocaine, amphetamines, opioids, nicotine, or alcohol). We discuss various animal models that are used to study drug addiction and dependence, with particular emphasis on investigations of the reward system, which acts as a convergent point for drug actions. We also discuss how gene-targeting technologies have advanced understanding of addictive behaviors and how animal research has informed clinical treatments of drug addiction. We conclude with thoughts about particularly promising directions for addiction research.
Criteria for the Development of a Valid Animal Model
Drug addiction is a disease characterized by compulsive, uncontrolled drug-seeking and drug-taking behavior that is very diffi cult to quit despite the user's recognition of its harmful consequences (Hasin et al. 2006) . Drug dependence is characterized by withdrawal symptoms in the absence of the drug that drive individuals to resume drug taking. For example, cocaine withdrawal produces profound fatigue, alcohol withdrawal produces anxiety and sometimes seizures, and opiate withdrawal results in marked dysphoria. Addicts resume drug taking to alleviate the negative symptoms of withdrawal, a phenomenon termed negative reinforcement.
Evidence indicates that, even in the absence of withdrawal symptoms, animals, like humans, self-administer psychoactive substances to experience the pleasurable (rewarding) effects of a drug. This phenomenon is termed positive reinforcement. Thus, a valid animal model of drug addiction should exhibit both negatively reinforced drug-seeking behavior to alleviate withdrawal symptoms and positively reinforced voluntary drugusing (drug self-administration) behavior to induce pleasurable sensations.
Because it is often impractical and unethical to perform research on addictive behavior in humans, the use of animal models makes it possible to gain insights essential for developing effective treatment strategies for such behavior. Animal models have become indispensable for the development of drug addiction treatments because they enable mapping of the specifi c regions of the brain where individual drugs exert their actions and determination of the mechanisms by which drugs produce their effects. Animal models also permit testing of the pharmacological effi cacy and verifi cation of the biosafety of medications before they are used in clinical practice (Lynch et al. 2010 ).
Negative Versus Positive Reinforcement Theories of Drug Addiction
Given the severity of withdrawal symptoms for many drugs, it is not surprising that negative reinforcement was the prevailing viewpoint during the early years of addiction research (discussed in Ahmed and Koob 1998; Ahmed et al. 2000) . A major scientifi c advance occurred when Olds and Milner (1954) reported a "positive reinforcement brain center" and demonstrated that rats self-administer electric stimulation at selective brain regions such as the nucleus accumbens (NAc 1 ) and ventral tegmental area (VTA 1 ). After many more years of research, it was determined that animals also self-administer psychoactive drugs into these brain areas even in the absence of withdrawal symptoms, thereby establishing the "reward" theory of drug self-administration (reviewed in Wise 1996) .
These studies determined that the positive reinforcement brain center fi rst described by Olds and Milner consists of VTA dopaminergic cell bodies and NAc terminals (Corbett and Wise 1980; Wise 1981) . In addition, investigators found that different drugs have different sites of action in the reward system. For example, the rewarding properties of morphine (opioids or opiates) are mediated by synapses at VTA dopamine cell bodies, alcohol reward is mediated by VTA neurons (Brodie et al. 1999) , and NAc dopamine terminals are the site of action for amphetamine and cocaine (Broekkamp et al. 1975; Colle and Wise 1988) .
Taken together, these observations indicate that the site of action that regulates the rewarding properties of drugs depends on the drug in question. Opiates and alcohol disinhibit VTA dopaminergic neuronal cell bodies, causing the release of dopamine at nerve terminals in the NAc. In contrast, cocaine and amphetamine exert their effects on dopaminergic neuronal terminals to increase dopamine concentrations at NAc synapses.
Modeling Relapse of Drug-Taking Behaviors in Animals
Many natural experiences important to survival are highly rewarding and cause increased dopamine release in the NAc.
The reward system is closely tied to the memory system, and associative memory processes linking positive emotions with certain experiences and behaviors help individuals fi nd the "right" kind of food, choose the "right" mate, and survive to pass on their genes (Kelley 2004) . Similarly, individuals remember the positive emotions caused by a psychoactive drug and its associated environmental cues.
Models that use the conditioned place preference (CPP 1 ) paradigm take advantage of these powerful and long-lasting memories for drug-associated environmental cues (conditioned stimuli) to evoke drug-seeking behavior (Hernandez and Kelley 2005; Robinson and Berridge 1993; Stewart et al. 1984) . For example, when morphine or cocaine treatment is paired with a specifi c environment, rats later spend significantly more time in the environment in which they received the drug.
Intracranial infusion of morphine into the VTA produces CPP (Bozarth et al. 1980; Olmstead and Franklin 1997; Phillips and LePiane 1980) , as does intracranial administration of amphetamine into the NAc (Josselyn and Beninger 1993; Schildein et al. 1998) . And conversely, when a given environment is paired with an aversive stimulus such as naloxone (an opioid antagonist), rats later avoid that environment (Mucha et al. 1982) , suggesting that the environment is perceived as a place of punishment. CPP is thus an extremely useful experimental tool for exploring associations between reward and memory systems and determining the reward value of different drugs.
Modeling Drug Self-Administration in Animals
Drug self-administration animal models developed over the past 40 years in an effort to mimic human drug addiction have helped pinpoint dopamine as a primary mediator of brain reward pathways where cocaine, amphetamines, and nicotine clearly act. In addition, the development of receptor gene research has been integral in determining that dopamine acts on D 1 to D 4 dopamine receptors coupled to G protein signaling systems (for review see Missale et al. 1998 ). Activation of these signaling pathways leads to changes in neuronal function that in turn result in the expression of addictive behavior(s) (Schultz 2010; Wise 2008) . Furthermore, glutamate, ␥-aminobutyric acid (GABA 1 ), serotonin, and norepinephrine play modulatory roles in regulating dopaminergic neuronal activity, making these neurotransmitters potential targets for drug addiction treatments (Kalivas and Volkow 2011) .
Several classes of psychoactive drugs-psychostimultants (e.g., cocaine, amphetamines), opioids, nicotine, and alcohol-are widely used in the population, and their chronic use causes signifi cant health problems and is of great concern to society. In the sections below, we discuss the animal models used to study self-administration of these drugs.
cocaine-insensitive mice, DAT-serotonin (SER) reuptake transporter (DAT/SER) double-KO mice, and dopaminedefi cient mice (Hnasko et al. 2007) . Data from these transgenic lines suggest that the dopaminergic system interacts with serotoninergic signaling to infl uence the acquisition of cocaine CPP (Hnasko et al. 2007 ). The involvement of serotonin and serotonin receptor subtypes in cocaine sensitization, discrimination, self-administration, reinstatement of cocaineseeking behavior, and CPP in laboratory animals has been reviewed elsewhere (Filip et al. 2010) .
Studies in rodents suggest that dopamine D 3 receptor antagonists (Song et al. 2012 ) and monoamine transporter inhibitors (Peng et al. 2010 ) reduce cocaine self-administration. A primary concern about using DAT inhibitors to treat cocaine addiction is that they may behave like cocaine and support self-administration. Data from DAT KI mice suggest that selective blockade of cocaine interactions with DAT may be an alternative approach to examine the role of DAT in cocaine addiction.
Treatment of cocaine addiction is a formidable clinical challenge (Somaini et al. 2011) . Therapeutic agents are not readily available, but animal and clinical research offers some promise for the development of potential treatments. For example, the dopamine agonist bromocriptine lowers the threshold for the rewarding effects of cocaine in rodents (Knapp and Kornetsky 1994; Ushijima et al. 1995; Weissenborn et al. 1996) , and controlled human trials have indicated that, in addition to bromocriptine, other such agonists (amantadine, carbamazepine, and desipramine) are effective in relieving some of the symptoms of cocaine abstinence (Withers et al. 1995) . However, the effi cacy of these treatments in a clinical setting has been mixed (Montoya et al. 2002) .
Amphetamines
Amphetamines (including methamphetamine and MDMA) work by different mechanisms to increase synaptic dopamine concentrations. Unlike cocaine, amphetamine blocks the vesicular transporter to reverse dopamine reuptake (release) (Seiden et al. 1993; Sulzer et al. 2005) .
In a DAT KO mouse model, the rewarding effects of amphetamine remained intact in the CPP paradigm. However, amphetamine-induced CPP is abolished by pretreatment of mice with a serotonin 5-HT1A antagonist (Budygin et al. 2004) . These results are consistent with the hypothesis that amphetamines interact not only with dopamine but also with serotonin and norepinephrine systems to exert their rewarding effects (Bhatia et al. 2011) .
Effi cacious pharmacological treatments for psychostimulant amphetamine addiction are not available in clinical practice despite the social problems associated with this drug (Huddleston et al. 2008) . But rodent models demonstrate that the memory system may be a candidate for treatment . For example, long-term methamphetamine exposure in the rat leads to motor sensitization, which can be prevented by combining the nonselective dopamine agonist pergolide with the 5-HT3
Psychostimulant Addiction
The most commonly abused schedule I or schedule IV 2 psychostimulants include cocaine, amphetamine, and 3,4-methylenedioxy-N-methamphetamine (MDMA 1 or "ecstasy").
All three psychostimulants increase synaptic dopamine concentrations, but their mechanisms of action differ. Cocaine inhibits the dopamine transporter and thus prevents reuptake of dopamine into presynaptic elements. Amphetamines produce their effects by reversing the reuptake of dopamine, serotonin, and/or norepinephrine in the brain (Gudelsky and Yamamoto 2008; Sager and Torres 2011) . MDMA also selectively targets the serotonin reuptake transporter (Seger 2010) . Repeated exposure to MDMA may lead to sensitization of dopaminergic responses to the substance, thereby increasing an individual's addiction risk (Schenk 2011; Schenk et al. 2011) . MDMA has recently gained tremendous popularity due to its availability.
Cocaine
Cocaine has been shown to interact with the dopamine transporter (DAT), so it was anticipated that knockout (KO 1 ) of the DAT gene would alter behaviors related to cocaine addiction such as cocaine self-administration and reward in the CPP paradigm. Overall, studies have demonstrated that cocaine-activated locomotor activity is decreased or eliminated in DAT knockouts; for example, Giros and colleagues (1996) reported that cocaine-induced locomotion and CPP are attenuated in DAT KO mice.
In contrast, cocaine self-administration patterns in DAT KO animals are less clear. Some studies suggest that such animals display substantially decreased self-administration (Thomsen et al. 2009a ), whereas others report that selfadministration is unaffected (Rocha et al. 1998; Tilley et al. 2007 ). Thus, unknown factors likely infl uence cocaine addictive behaviors to cause different study outcomes.
Another problem with DAT knockout is that signifi cant compensatory changes can occur in KO animals. To overcome potential compensation caused by gene deletion, Chen and colleagues (2006) used a knock-in (KI) mouse line carrying a functional but cocaine-insensitive DAT. In these mice, cocaine administration suppressed locomotor activity, did not increase extracellular dopamine levels in the NAc, and failed to produce cocaine reward. Furthermore, the mice did not selfadminister cocaine (Thomsen et al. 2009b) . Thus a functional DAT is necessary and suffi cient to maintain cocaine addiction.
In addition to the DAT KO and KI animals, other transgenic mice have been developed to study the effects of cocaine: DAT-overexpressing transgenic mice (Donovan et al. 1999) , vesicular monoamine transporter KO mice (VMAT2), antagonist ondansetron (Bhatia et al. 2011 ). Thus, drug-seeking behavior can be reversed in addicted animals by administering fi rst a selective dopamine agonist to "reactivate" the addiction "circuit" and then a 5-HT3 antagonist to block memory reconsolidation of methamphetamine sensitization and addiction (Bhatia et al. 2011 ). This approach holds promise for new pharmacological treatment of stimulant addiction including cocaine and amphetamines.
Opioids
The opioid analgesics-morphine, diacetylmorphine (heroin), and other compounds that share morphine-like propertiesproduce rewarding effects through their actions on endogenous opioid receptors, and frequent use leads to tolerance and dependence.
Mechanisms
Opioids activate µ and ␦ opioid receptors in the VTA and NAc, leading to the release of dopamine (Hirose et al. 2005; Yoshida et al. 1999 ). In the VTA, opioid-activated µ opioid receptors result in decreased GABA inhibition (disinhibition of GABAergic neurons) (Johnson and North 1992) .
Studies using animal models have shown that opioid agonists with selective affi nity to µ opioid receptors possess the highest abuse potential (Devine and Wise 1994) , but ␦ opioid receptor agonists can also induce rewarding effects in animals (Hutcheson et al. 2001) . Pharmacological studies have shown that ␦ opioid receptors are about 100 times less effective than µ opioid receptors in maintaining intracranial self-administration and striatal dopamine release (Devine et al. 1993) .
The opioid receptors appear to play a negative regulatory role such that agonists increase brain reward thresholds for intracranial self-administration (Beguin et al. 2008; Carlezon et al. 2006 ) and cause aversive effects (Land et al. 2008) . In addition, receptor gene knockout results in elevated dopamine levels in the NAc (Chefer et al. 2005) , indicating that this knockout may directly alter the rewarding property of opioids.
Future treatment strategies will benefi t from the outcome of studies using various opioid receptor transgenic animals to map the involvement of these receptor subtypes on opioid tolerance, dependence, and self-administration.
Treatment
Treatment of opioid addiction is a two-step process that involves detoxifi cation and relapse prevention. Detoxifi cation is designed to remove the drug from the patient, but withdrawal symptoms occur when addicts stop using opioids and often are severe enough to cause relapse into drug-taking behavior.
Because treatment of opioid addiction by detoxifi cation alone leads to high rates of relapse (Lobmaier et al. 2010) , the most effective means of relapse prevention is agonist replacement therapy (Lobmaier et al. 2010; Veilleux et al. 2010 ). This treatment involves use of a less effi cacious and longer-acting opioid agonist to decrease the frequency of drug taking. For example, buprenorphine is a µ opioid receptor partial agonist that dissociates slowly from the receptor and thus produces smaller effects and prolonged duration of actions.
Methadone is the most common replacement medication, typically presented in a tapered procedure during 10 to 28 days of detoxifi cation (Gossop et al. 1989; Strang and Gossop 1990) . Buprenorphine, buprenorphine-naloxone, and other opioid agonists such as heroin, slow-release oral morphine, codeine, and levomethadyl acetate hydrochloride (LAAM) are also used (Veilleux et al. 2010 ). In addition, buprenorphine, clonidine, or lofexidine are sometimes used to decrease craving (Gossop 1988; Gowing et al. 2009 ).
Nicotine
Mechanisms
Nicotine is the major active component in tobacco smoke that supports smoking behavior and nicotine addiction (Polosa and Benowitz 2011) . It works by activating brain nicotinic receptors (nAChRs), which are ligand-gated cation channels that conduct Na + , K + , and/or Ca 2+ currents (Taly et al. 2009 ). nAChRs are formed from different subunits, ␣2-9 and ␤2-4, that are encoded by 17 different genes. The two main types of nAChRs that have been identifi ed are the homo-oligomer receptors (e.g., the ␣7 nAChRs) and the hetero-oligomer receptors (e.g., the ␣4␤2 nAChRs and other oligomers). The ␣7 receptors, present in many brain areas, are characterized by fast activation, low ligand affi nity, and high Ca 2+ permeability. In contrast, the ␣4␤2 nAChRs are high-affi nity and slowdesensitizing receptors. Nicotine activates nAChRs in the VTA (␣4␤2, ␣5␤2, ␣6␤2, ␣6␤3, ␣3␤4, and ␣7 isoforms) and NAc (␣4␤2, ␣4␣5␤2, ␣6␤2␤3, and ␣6␣4␤␤3 isoforms), leading to dopamine release in these brain areas that mediates reward.
Gene deletion studies have been useful in determining the involvement of specifi c nAChR isoforms in nicotine selfadministration. For example, mice lacking ␤2, ␣4, or ␣6 subunits do not self-administer nicotine, but do so when these receptor subunits are reexpressed in the VTA. In contrast, ␣7 gene knockout did not affect nicotine self-administration (Pons et al. 2008) . Moreover, deletion of ␣5 or overexpression of ␤4 increased nicotine self-administration. ␣5 subunit, which is highly expressed in dopaminergic neurons (Klink et al. 2001) , regulates nicotine self-administration in an animal model of nicotine addiction (Changeux 2010) .
Treatment
There have been signifi cant efforts in recent years to promote smoking cessation, but cessation is different from the treatment of nicotine addiction.
The current practice for smoking cessation is to use nicotine patches to sustain nicotine addiction without smoking. To cure the addiction, however, one must stop taking nicotine, and currently there is no effective therapy for this condition.
Clinical practice suggests that nicotine replacement therapy (bupropion, varenicline, and other nicotinic receptor partial agonists) and second-line medications such as nortriptyline and clonidine can ease craving (Fiore and Jaen 2008; Polosa and Benowitz 2011) . In addition to dopamineand serotonin-based drugs, glutamatergic medications may be useful for the treatment of nicotine addiction (Olive et al. 2012) as preclinical studies suggest that glutamatergic transmission plays a critical role in drug addiction including drug reward, reinforcement, and relapse (Bird and Lawrence 2009; Moussawi and Kalivas 2010 ). Various other drugs tested for their treatment potential in nicotine addiction are discussed in a review by Polosa and Benowitz (2011) .
Alcohol
Alcohol abuse does not fully conform to the same compulsive behavioral characteristics-uncontrolled drug seeking and drug taking-associated with addictions to drugs such as cocaine, nicotine, amphetamine, and opiates. Indeed, signifi cant disagreements in both the clinical and research communities have surrounded the adoption of the term addiction for alcohol abuse; instead, alcohol dependence or alcoholism is usually used (O'Brien 2011; Ripley and Stephens 2011) .
Given the disagreements about the defi nition of human alcoholism, it is perhaps not surprising that modeling alcohol addiction in animals is complicated. There is no single paradigm that models all characteristics of alcohol dependence (Ripley and Stephens 2011) . Instead, investigators separately model specifi c subcomponents of alcohol dependence, such as voluntary intake (Goldstein 1977) , increased consumption (Falk et al. 1972) , preference (Myers and Veale 1968) (Erwin and Deitrich 1996) , and withdrawal behavior (Crabbe et al. 1990) .
The fi rst challenge in modeling alcohol use and abuse has been that most laboratory animals do not fi nd alcohol palatable; they therefore do not consume it unless they are water deprived or sweetening agents have been added. Although it is possible that many human alcoholics also start with sweetened alcoholic beverages (e.g., during adolescence), laboratory animals rarely compulsively self-administer large quantities of alcohol for long durations as seen in human alcoholism. Thus, signifi cant attention has been given to developing animal models of alcohol consumption behavior.
Given that the fi rst step in becoming addicted to alcohol is to consume alcohol, animal models of alcohol consumption enhance understanding of the neurobiology and genetics of this behavior. Such models may reveal factors that regulate alcohol intake in both normal and diseased states of alcohol consumption behavior.
Models of Alcohol Consumption
One feature of alcoholism is the consumption of large quantities of alcohol. It is known that animals may drink alcohol for caloric purposes. However, a rat that drinks alcohol for the pharmacological effects must consume enough alcohol to have a blood ethanol concentration (BEC) of 80 to 100 mg/dL.
Among the fi ve rat lines genetically selected for high alcohol consumption, Sinclair and colleagues (1989) developed the ALKO AA (alcohol-preferring) rats, which prefer 10% alcohol solution over water. They differ from the nonpreferring (ANA) line of rats in alcohol-related reinforcement behaviors, alcohol metabolism, alcohol tolerance, and alcohol-induced neurochemical changes (Kiianmaa et al. 1991) .
The second line is the Sardinian alcohol-preferring line of rats (sP; Colombo 1997), which consume more than 4 g/kg of 10% alcohol solution during the fi rst alcohol drinking session and can drink up to 6 g/kg of alcohol in subsequent weeks. They are reported to achieve pharmacologically relevant BEC at each drinking session and to exhibit "binge"-like drinking behavior (i.e., three drinking bouts per day; Loi et al. 2010) .
The third line, Marchigian Sardinian (msP) rats, was genetically selected for the animals' high alcohol preference from the original sP rats (Ciccocioppo et al. 1998) . Although the msP rats share many of the sP rats' phenotypic traits (e.g., alcohol preference and binge-like drinking behavior), they are also highly vulnerable to stress-induced relapse of alcohol consumption (Ciccocioppo et al. 2006) . Indeed, they exhibit many of the behavioral traits of human alcoholics.
The fourth line of "alcoholic" rat was selectively bred to exhibit high alcohol consumption, resulting in the highly useful alcohol-preferring P rat line at Indiana University (Li et al. 1987) . P rats exhibit voluntary alcohol consumption of 10 to 30% alcohol solution to the point of intoxication, and bar-press to self-administer alcohol resulting in pharmacologically relevant BECs (in the range of 50-200 mg%; McBride and Li 1998). P rats also show binge-like drinking patterns during the dark cycle, consuming about 6 g/kg of ethanol during a 1-hour access period (Bell et al. 2006) . In addition to consuming high quantities of alcohol, P rats are less sensitive to the sedative and aversive effects of alcohol (Stewart et al. 1996) , exhibit greater responses to its euphoric (stimulatory) properties (Bell et al. 2006) , and show enhanced anxiety-related behaviors (Stewart et al. 1993) . The P rats self-administer alcohol in a variety of experimental paradigms (e.g., intragastric, intracranial, and operant administration; Bell et al. 2006 ) and work very hard to obtain alcohol (Penn et al. 1978) . Thus, the P rat appears to be a valid animal model for human alcoholism (Li et al. 1987) .
The fi fth rat line is the UCh-B line. In the 1940s, researchers at the University of Chile used genetic selection to develop a rat model for high alcohol consumption, resulting in the selection and breeding of high-and low-alcohol-consuming rats (UCh-abstainer, or UCh-A, and UCh-bibulous, or UCh-B, respectively) (Tampier et al. 1984) . Although these animals were the earliest known strains of rats that differ in alcohol preference, they were not widely used in alcohol research outside South America. Thus, the validity of this rat strain as a model for alcohol addiction research remains to be determined.
Models of Binge Drinking
Binge drinking is defi ned as a pattern of alcohol consumption that results in a BEC of more than 80 mg% in about 2 hours ). This clearly harmful drinking behavior (NIAAA Newsletter 2004) is practiced by a growing number of young drinkers: the 2010 NIDA-sponsored Monitoring the Future Survey reports that rates of binge drinking (defi ned as fi ve or more drinks in a row in the previous 2-week period) were a worrisome 8%, 16%, and 25% among 8 th , 10 th , and 12 th graders, respectively. The age of drinking onset is of particular concern given the link between adolescent binge drinking and the likelihood of later addiction (Enoch 2011) : individuals who start drinking at ages 14 to 16 are four times more likely to become alcohol dependent than those who begin drinking at age 21 (Hingson et al. 2006 ).
Both human and animal studies suggest that binge-like alcohol exposure during adolescence is particularly harmful to brain and behavioral development. It is not known, however, how normal adolescent changes in psychosocial, endocrine, and brain function increase risky behaviors such as alcohol use, and how early alcohol use in turn alters the trajectory of adolescent development toward addiction risk. Animal models and controlled environmental conditions are necessary for disentangling these issues, especially given that alcohol use in humans is often accompanied by other potential mediating factors such as stress and drug use. Thus, it is important to include developmental aspects in animal models of alcohol abuse to improve scientifi c understanding of the etiology of alcoholism.
Animal studies should also model key aspects of human adolescent alcohol use such as increased alcohol intake relative to adults and binge drinking to intoxication. Rodent models are emerging that meet these criteria for adolescent drinking. For example, investigators have studied adolescent rats and mice that voluntarily drink more than adults under both continuous-access (Doremus et al. 2005; Tolliver and Samson 1991; Truxell et al. 2007; Vetter et al. 2007 ) and limited-access conditions (Maldonado-Devincci et al. 2010; Metten et al. 2011 ). In addition, some adolescent rodents actually do drink to intoxication, especially when tested in limited-access paradigms (Rhodes et al. 2005; Strong et al. 2010) .
Limited-access paradigms have been particularly valuable in inducing adolescent binge-drinking behavior. "Drinking in the dark" (DID) models allow temporary access (2-4 hours) to alcohol during the dark phase of the light:dark cycle, when animals are most active. Although overall alcohol intake is lower relative to continuous-access drinking paradigms, animals drink to intoxication in a short period of time and consume more alcohol per drinking bout (Rhodes et al. 2005) .
Recent data also demonstrate that limited access to alcohol during adolescence causes increased baseline (Metten et al. 2011; Strong et al. 2010 ) and dependence-related alcohol consumption in adulthood (Gilpin et al. 2012 ). Thus, limitedaccess adolescent drinking paradigms appear to be successful in modeling both the binge-like pattern of adolescent drinking behavior and the consequences of adolescent alcohol consumption on adult alcohol use and risk of dependence.
The addictive properties of alcohol may be mediated by GABA neural transmission. Alcohol has been shown to disinhibit VTA GABA neurons (Brodie et al. 1999) , resulting in the release of dopamine in the NAc. Connexin-36 (Cx36) gap junctions regulate the functional activity of GABA neurons in the VTA. Cx36 KO mice exhibit less motor impairment by acute alcohol administration and drink signifi cantly less alcohol than wild types in a binge DID paradigm. Decreased drinking in Cx36 KO mice may be due to a diminished hedonic valence for alcohol (Steffensen et al. 2011 ). GABA A receptors are known to mediate various effects of alcohol including behavioral sensitivity and consumption (for review see Boehm et al. 2006) . GABA A receptors are composed of ␣1-6, ␤2-3, ␥2, and/or ␦ subunits, and these receptor activities are determined by the composition of subunits. For example, ␦ subunit KO resulted in signifi cantly lower alcohol consumption (Mihalek et al. 2001 ), but ␣5 subunit gene deletion had no effect on alcohol reward (Stephens et al. 2005) . Moreover, mice lacking PKCepsilon (PKC) drink less alcohol and show greater alcohol sensitivity Wallace et al. 2007 ). However, systematic studies are needed to validate these models for altering alcohol consumption.
Treatment
Treatments for alcohol abuse have not advanced much since the early 1900s. Disulfi ram (Antabuse), used to deter individuals from drinking alcohol, has been prescribed in clinical practice since the 1940s. This drug prevents aldehyde dehydrogenase from breaking down acetaldehyde to form acetic acid, resulting in a buildup of acetaldehyde in the body that causes aversive reactions such as fl ushing, increased heart rate, and nausea. Given these adverse effects, the primary barrier for employing disulfi ram as a clinical treatment is patient compliance; thus a disulfi ram implant is a treatment choice for some medical practitioners.
Neurobiological research using animal models indicates that opioid receptors and ␤-endorphin systems modulate alcohol consumption behavior, presumably via the corticomesolimbic dopamine system (Anton 2008; Haile et al. 2008; Rosner et al. 2010) . For example, opioid receptor antagonists such as naltrexone and nalmefene reduce alcohol consumption (Garbutt 2010; Lobmaier et al. 2010; Rosner et al. 2010) . Recent studies also suggest that gamma-hydroxybutyric acid (Addolorato et al. 2009 ), acamprosate (Mann et al. 2008) , baclofen , and desipramine ) may have potential for the treatment of alcohol dependence, most likely through varied and unidentifi ed mechanisms. This variability is not surprising given that alcohol addiction is a polygenic disease that involves many neurobiological pathways and numerous genes (for review see Goldman et al. 2005 ). As such, fi nding an effective treatment for alcohol addiction is a signifi cant scientifi c challenge.
Perspectives and Other Considerations
One promising area of addiction research is the study of the interactions between memory and reward neural circuitry. It is clear from the literature that relapse into drug seeking is a key feature of addiction, and that drug-seeking behavior for all classes of drugs is driven in part by associations formed between drug-related stimuli and the rewarding effects of a drug (Miller and Marshall 2005) .
Associations between drug-paired cues and the rewarding effects of a drug can be conceptualized as an "addiction memory" (Kelley 2004) . In this view, addiction is composed of two primary processes-the acquisition and the extinction of the cue-paired reinforcing effects of a drug. Thus, failure to extinguish an acquired "memory of addiction" may lead to relapse.
In line with this reasoning, recent studies have emphasized the importance of drug-cue extinction in addiction treatment (Dhonnchadha and Kantak 2011; Weiss 2010) . Extinction is not memory erasure per se but rather involves the formation of new memories that inhibit the existing memory. Interestingly, the process of extinction is sensitive to different memoryforming techniques as well as to medications that improve memory and enhance the effi cacy of exposure therapy (Taylor et al. 2009 ).
In addition to extinction processes, other means of disrupting addiction memories are available; for example, interfering with drug memory reconsolidation shows some promise (Milton and Everitt 2010; Milton et al. 2012) . Memory reconsolidation, considered to be a process distinct from extinction, occurs immediately after a memory is reactivated or retrieved, when the newly retrieved memory is vulnerable to modifi cation. Thus, manipulating memory reconsolidation processes may disrupt cue-drug memories in animal models of drug relapse. For example, despite evidence that cocaine addiction is resistant to extinction (Weiss et al. 2001) , recent work using a CPP model demonstrated that the N-methyl-d-aspartate (NMDA) antagonist MK-801 disrupts reconsolidation of cocaine-associated memories in rats (Brown et al. 2008) and that the addiction memory can thus be "erased" by manipulating reconsolidation processes.
A greater combined understanding of the neurobiological processes involved in memory extinction and reconsolidation will support the development of effi cacious medications for the therapeutic treatment of drug addiction.
